Quick Facts -AI IVF
- Conceivable Life Sciences raised $50 million Series A led by Advance Venture Partners in September 2025 bringing total funding to $70 million for AURA, world’s first AI IVF automated laboratory platform.
- Dr. Stephanie Kuku, Chief Knowledge Officer at Conceivable, told Fox News AI IVF could reduce cycle numbers and increase conception chances through robotic precision automating 200+ intricate embryo creation steps.
- Company achieved world’s first fully automated intracytoplasmic sperm injection remotely with embryologist in New York controlling process for reproductive cells 3,000 miles away demonstrating robotics sophistication.
- Conceivable’s IRB study resulted in 22 pregnancies with clinical outcomes rivaling world’s top IVF labs while company targets 70% cost reduction from current $15,000-$20,000 per cycle to roughly $4,500.
- AI IVF technology addresses supply-demand mismatch where 1 in 6 couples suffer from infertility yet over 90% cannot access treatment due to high costs, clinic capacity constraints, and geographic limitations.
- Global IVF market valued at $26.5 billion in 2023 projected to exceed $35 billion by 2030 with AI automation promising to democratize Nobel Prize-winning therapy currently functioning as “concierge medicine.”
- Traditional AI IVF labs remain largely manual and artisanal introducing tremendous variability and inconsistent outcomes that automated systems standardize through computer vision, robotics, and algorithmic precision.
Inside the Move
Conceivable’s AI IVF approach tackles the core paradox that despite clinical advances since Louise Brown’s 1978 birth, laboratory processes haven’t adopted automation seen in other medicine branches.
The company synthesizes AI and robotics to eliminate human hand-and-eye variability in delicate single-cell surgery where sperm-egg combination precision determines embryo viability.
Success rates for women under 35 improved from 5% in 1980s to 42.8% by 2023, but manual processes create bottlenecks limiting access as demand outpaces embryologist supply by factor of 10.
Momentum Tracker
🔺 Automated fertility technology providers: Conceivable’s AI IVF platform attracting $70 million demonstrates investor conviction that robotics-driven standardization solves IVF’s accessibility crisis.
This validates automated lab business models promising to scale Nobel Prize therapy from niche treatment serving high-income patients to mainstream option through cost reduction and capacity expansion.
Multiple competitors including AutoIVF, Fertilis, and Overture Life Sciences now developing similar AI IVF systems accelerating sector transformation toward technology-enabled democratization of reproductive medicine globally.